Skin patch and vaginal ring versus combined oral contraceptives for contraception

Cochrane Database of Systematic Reviews

Volumn 2013, Issue 4, 2013, Pages

  Lopez, Laureen M ^a   Grimes, David A ^b   Gallo, Maria F ^c   Stockton, Laurie L ^a   Schulz, Kenneth F ^b  

^a FAMILY HEALTH INTERNATIONAL   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c NATIONAL CENTER FOR CHRONIC DISEASE PREVENTION AND HEALTH PROMOTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DESOGESTREL PLUS ETHINYLESTRADIOL; DROSPIRENONE PLUS ETHINYLESTRADIOL; ETHINYLESTRADIOL PLUS ETONOGESTREL; ETHINYLESTRADIOL PLUS GESTODENE; ETHINYLESTRADIOL PLUS LEVONORGESTREL; ETHINYLESTRADIOL PLUS NESTORONE; ETHINYLESTRADIOL PLUS NORELGESTROMIN; ETHINYLESTRADIOL PLUS NORGESTIMATE; LEVONORGESTREL; ORAL CONTRACEPTIVE AGENT; PLACEBO; UNCLASSIFIED DRUG; CONTRACEPTIVE AGENT;

ABDOMINAL PAIN; ACNE; AMENORRHEA; BODY WEIGHT GAIN; BREAST DISEASE; BREAST TENDERNESS; CONTRACEPTION; CONTRACEPTIVE BEHAVIOR; CONTRACEPTIVE EFFECTIVENESS; DATA SYNTHESIS; DEPRESSION; DEVICE SAFETY; DIZZINESS; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSMENORRHEA; EMOTIONAL DISORDER; FATIGUE; FEMALE GENITAL PRURITUS; HEADACHE; HOT FLUSH; HUMAN; HYPERTENSION; INTERMETHOD COMPARISON; IRRITABILITY; LEG PAIN; LEUKORRHEA; LIBIDO DISORDER; MASTALGIA; MEDICATION COMPLIANCE; MENSTRUAL CYCLE; METRORRHAGIA; MIGRAINE; MOOD DISORDER; MUSCLE CRAMP; NAUSEA; NERVOUSNESS; ORAL CONTRACEPTIVE USE; OUTCOME ASSESSMENT; OVULATION INHIBITION; PATIENT COMPLIANCE; PATIENT SATISFACTION; PREGNANCY RATE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; SEXUAL BEHAVIOR; SEXUAL DYSFUNCTION; SEXUAL SATISFACTION; SIDE EFFECT; SINUSITIS; SPOTTING; SYSTEMATIC REVIEW; URINARY TRACT INFECTION; VAGINA DISCHARGE; VAGINA DISEASE; VAGINA IRRITATION; VAGINA MYCOSIS; VAGINAL DRYNESS; VAGINITIS; VOMITING; WITHDRAWAL BLEEDING; CONSUMER; DRUG EFFECT; DRUG IMPLANT; FEMALE; FEMALE CONTRACEPTIVE DEVICE; META ANALYSIS; PREGNANCY;

CONSUMER SATISFACTION; CONTRACEPTIVE AGENTS, FEMALE; CONTRACEPTIVE DEVICES, FEMALE; CONTRACEPTIVES, ORAL, COMBINED; DRUG IMPLANTS; FEMALE; HUMANS; MEDICATION ADHERENCE; MENSTRUAL CYCLE; PREGNANCY; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84886841854     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD003552.pub4     Document Type: Review

References (81)

1. Ahrendt H-J, Nisand I, Bastianelli C, Gómez AM, Gemzell-Danielsson K, Urdl W, et al.Efficacy, acceptability and tolerability of the combined contraceptive ring, NuvaRing, compared with an oral contraceptive containing 3 μg of ethinyl estradiol and 3 mg of drospirenone. Contraception 2006;74(6):451-7.
2. Milsom I, Lete I, Bjertnaes A, Rokstad K, Lindh I, Gruber CJ, et al.Effects on cycle control and bodyweight of the combined contraceptive ring, NuvaRing, versus an oral contraceptive containing 30 μg ethinyl estradiol and 3 mg drospirenone. Human Reproduction 2006;21(9):2304-11.
3. Audet MC, Moreau M, Koltun WD, Waldbaum AS, Shangold G, Fisher AC, et al.Evaluation of contraceptive efficacy and cycle control of a transdermal contraceptive patch vs an oral contraceptive: a randomized controlled trial. Journal of the American Medical Association 2001;285(18):2347-54.
4. Boonyarangkul A, Taneepanichskul S. Comparison of cycle control and side effects between transdermal contraceptive patch and an oral contraceptive in women older than 35 years. Journal of the Medical Association of Thailand 2007;90(9):1715-9.
5. Dittrich R, Parker L, Rosen JB, Shangold G, Creasy GW, Fisher AC. Transdermal contraception: evaluation of three transdermal norelgestromin/ethinyl estradiol doses in a randomized, multicenter, dose-response study. American Journal of Obstetrics and Gynecology 2002;186(1):15-20.
6. Duijkers I, Killick S, Bigrigg A, Dieben TO. A comparative study on the effects of a contraceptive vaginal ring NuvaRing and an oral contraceptive on carbohydrate metabolism and adrenal and thyroid function. European Journal of Contraception and Reproductive Health Care 2004;9(3):131-40.
7. Elkind-Hirsch KE, Darensbourg C, Ogden B, Ogden LF, Hindelang P. Contraceptive vaginal ring use for women has less adverse metabolic effects than an oral contraceptive. Contraception 2007;76(5):348-56.
8. Gilliam M L, Neustadt A, Kozloski M, Mistretta S, Tilmon S, Godfrey E. Adherence and acceptability of the contraceptive ring compared with the pill among students: a randomized controlled trial. Obstetrics and Gynecology 2010;115(3):503-10.
9. Hughey A B, Neustadt A B, Mistretta S Q, Tilmon S J, Gilliam M L. Daily context matters: predictors of missed oral contraceptive pills among college and graduate students. American Journal of Obstetrics and Gynecology 2010;203(4):323 e1-7.
10. Guida M, Di Spiezio Sardo A, Bramante S, Sparice S, Acunzo G, Tommaselli GA, et al.Effects of two types of hormonal contraception--oral versus intravaginal--on the sexual life of women and their partners. Human Reproduction 2005;20(4):1100-6.
11. Kaunitz A, Archer DF, Foegh M. Increased compliance with a low-dose combination contraceptive patch (AG200-15) compared with a low-dose combination oral contraceptive (COC) in a Phase 3 clinical trial (abstract). Contraception 2012;86(2):178.
12. Kaunitz A, Foegh M, Mishell D. Increased compliance independent of patient demographics with a low-dose combination contraceptive patch (AG200-15) compared with a low-dose combination oral contraceptive in a Phase 3 clinical trial (abstract). Contraception 2012;86(3):314.
13. Kaunitz AM, Mishell DR, Foegh M. Comparative Phase 3 study of AG200-15, a low-dose estrogen and levonorgestrel contraceptive patch. http://www.agiletherapeutics.com/Clinical_support.html (accessed 26 Sep 2012).
14. Kluft C, Mayer G, Helmerhorst FM, Hall H, Creasy G. Comparison of the effects of a contraceptive patch and oral contraceptives on coagulation parameters [abstract no. FC2.30.04]. International Journal of Gynaecology and Obstetrics 2000;70(Suppl 2):B77.
15. Kluft C, Meijer P, LaGuardia KD, Fisher AC. Comparison of a transdermal contraceptive patch vs. oral contraceptives on hemostasis variables. Contraception 2008;77(2):77-83.
16. Mohamed A M, El-Sherbiny W S, Mostafa W A. Combined contraceptive ring versus combined oral contraceptive (30-mug ethinylestradiol and 3-mg drospirenone). International Journal of Gynaecology and Obstetrics 2011;114(2):145-8.
17. Oddsson K, Leifels-Fischer B, de Melo NR, Wiel-Masson D, Benedetto C, Verhoeven CHJ, et al.Efficacy and safety of a contraceptive vaginal ring (NuvaRing) compared with a combined oral contraceptive: a 1-year randomized trial. Contraception 2005;71(3):176-82.
18. Oddsson K, Leifels-Fischer B, Wiel-Masson D, de Melo NR, Benedetto C, Verhoeven CHJ, et al.Superior cycle control with a contraceptive vaginal ring compared with an oral contraceptive containing 30 μg ethinylestradiol and 150 μg levonorgestrel: a randomized trial. Human Reproduction 2005;20(2):557-62.
19. Rad M, Kluft C, Menard J, Burggraaf J, de Kam ML, Meijer P, et al.Comparative effects of a contraceptive vaginal ring delivering a nonandrogenic progestin and continuous ethinyl estradiol and a combined oral contraceptive containing levonorgestrel on hemostasis variables. American Journal of Obstetrics and Gynecology 2006;195(1):72-7.
20. Sitruk-Ware RL, Menard J, Rad M, Burggraaf J, de Kam ML, Tokay BA, et al.Comparison of the impact of vaginal and oral administration of combined hormonal contraceptives on hepatic proteins sensitive to estrogen. Contraception 2007;75(6):430-7.
21. Sabatini R, Cagiano R. Comparison profiles of cycle control, side effects and sexual satisfaction of three hormonal contraceptives. Contraception 2006;74(3):220-3.
22. Stewart FH, Brown BA, Raine TR, Weitz TA, Harper CC. Adolescent and young women's experience with the vaginal ring and oral contraceptive pills. Journal of Pediatric and Adolescent Gynecology 2007;20(6):345-51.
23. Hedon B, Helmerhorst FM, Cronje HS, Shangold G, Fisher A, Creasy G. Comparison of efficacy, cycle control, compliance and safety in users of a contraceptive patch vs an oral contraceptive. International Journal of Gynaecology and Obstetrics 2000;70(Suppl 2):B78.
24. Urdl W, Apter D, Alperstein A, Koll P, Schönian S, Bringer J, et al.Contraceptive efficacy, compliance and beyond: factors related to satisfaction with once-weekly transdermal compared with oral contraception. European Journal of Obstetrics & Gynecology and Reproductive Biology 2005;121(2):202-10.
25. Veres S, Miller L, Burington B. A comparison between the vaginal ring and oral contraceptives. Obstetrics and Gynecology 2004;104(3):555-63.
26. O'Connell KJ, Osborne LM, Westhoff C. Measured and reported weight change for women using a vaginal contraceptive ring vs. a low-dose oral contraceptive. Contraception 2005;72(5):323-7.
27. Schafer JE, Osborne LM, Davis AR, Westhoff C. Acceptability and satisfaction using Quick Start with the contraceptive vaginal ring versus an oral contraceptive. Contraception 2006;73(5):488-92.
28. Westhoff C, Osborne LM, Schafer JE, Morroni C. Bleeding patterns after immediate initiation of an oral compared with a vaginal hormonal contraceptive. Obstetrics and Gynecology 2005;106(1):89-96.
29. Archer D, Bigrigg A, Smallwood G, Shangold G, Creasy G. An integrated assessment of patient compliance with a weekly contraceptive patch (ORTHO EVRA / EVRA). Fertility and Sterility 2001; Vol. 76 (3 Suppl 1):20.
30. Archer DF, Bigrigg A, Smallwood GH, Shangold GA, Creasy GW, Fisher AC. Assessment of compliance with a weekly contraceptive patch (Ortho Evra™/Evra™) among North American women. Fertility and Sterility 2002;77:27-31.
31. Archer DF, Cullins V, Creasy GW, Fisher AC. The impact of improved compliance with a weekly contraceptive transdermal system (Ortho Evra) on contraceptive efficacy. Contraception 2004;69:189-95.
32. Bednarek PH, Nichols MD, Carlson N, Edelman AB, Creinin MD, Truitt S, et al.Effect of "observed start" vs. traditional "Sunday start" on hormonal contraceptive continuation rates after medical abortion. Contraception 2008;78(1):26-30.
33. Bjarnadottir RI, Tuppurainen M, Killick SR. Comparison of cycle control with a combined contraceptive vaginal ring and oral levonorgestrel/ethinyl estradiol. American Journal of Obstetrics and Gynecology 2002;186:389-95.
34. Bustillos-Alamilla E, Zepeda-Zaragoza J, Hernandez-Ruiz M A, Briones-Landa C H. Combined hormonal contraception in cycles artificially extended [Anticoncepcioćn con hormonales combinados en ciclos extendidos artificialmente]. Ginecología de Obstetricia de México 2010;78(1):37-45.
35. Creasy G, Hall N, Shangold G. Patient adherence with the contraceptive patch dosing schedule versus oral contraceptives. Obstetrics and Gynecology 2000; Vol. 95:S60.
36. Duijkers IJM, Klipping C, Verhoeven CHJ, Dieben TOM. Ovarian function with the contraceptive vaginal ring or an oral contraceptive: a randomized study. Human Reproduction 2004;19:2668-73.
37. Duijkers IJM, Verhoeven CHJ, Dieben TOM, Klipping C. Follicular growth during contraceptive pill or vaginal ring treatment depends on the day of ovulation in the pretreatment cycle. Human Reproduction 2004;19:2674-9.
38. Guazzelli CA, Barreiros FA, Barbosa R, Torloni MR, Barbieri M. Extended regimens of the contraceptive vaginal ring versus hormonal oral contraceptives: effects on lipid metabolism. Contraception 2011.
39. Mulders TM, Dieben TO. Use of the novel combined contraceptive vaginal ring NuvaRing for ovulation inhibition. Fertility and Sterility 2001;75:865-70.
40. Pierson RA, Hess AR, Archer DF, Parsons K, Shangold G, Fisher A, et al.Effects of a contraceptive patch and 3 oral contraceptives on follicular development following incorrect dosing [abstract no. FC2.30.08]. International Journal of Gynaecology and Obstetrics 2000;70:78.
41. Pierson RA, Archer DF, Moreau M, Shangold GA, Fisher AC, Creasy GW. Ortho Evra/Evra versus oral contraceptives: follicular development and ovulation in normal cycles and after an intentional dosing error. Contraception 2003;80:34-42.
42. Roumen FJ, Dieben TO. Comparison of uterine concentrations of ethinyl estradiol and etonogestrel after use of a contraceptive vaginal ring and an oral contraceptive. Fertility and Sterility 2006;85:57-62.
43. Sibai BM, Odlind V, Meador ML, Shangold GA, Fisher AC, Creasy GW. A comparative and pooled analysis of the safety and tolerability of the contraceptive patch (Ortho Evra™/Evra™). Fertility and Sterility 2002;77:19-26.
44. Smallwood GH, Meador ML, Lenihan JP, Shangold GA, Fisher AC, Creasy GW. Efficacy and safety of a transdermal contraceptive system. Obstetrics and Gynecology 2001;98(5 Pt 1):799-805.
45. Timmer CJ, Mulders TM. Pharmacokinetics of etonogestrel and ethinylestradiol released from a combined contraceptive vaginal ring. Clinical Pharmacokinetics 2000;39:233-42.
46. Van den Heuvel MW, van Bragt AJ, Alnabawy AK, Kaptein MC. Comparison of ethinylestradiol pharmacokinetics in three hormonal contraceptive formulations: the vaginal ring, the transdermal patch and an oral contraceptive. Contraception 2005;72:168-74.
47. White T, Jain JK, Stanczyk FZ. Effect of oral versus transdermal steroidal contraceptives on androgenic markers. American Journal of Obstetrics and Gynecology 2005;192:2055-9.
48. White T, Özel B, Jain JK, Stanczyk FZ. Effects of transdermal and oral contraceptives on estrogen-sensitive hepatic proteins. Contraception 2006;74:293-6.
49. Zacur HA, Hedon B, Mansour D, Shangold GA, Fisher AC, Creasy GW. Integrated summary of Ortho Evra™/Evra™ contraceptive patch adhesion in varied climates and conditions. Fertility and Sterility 2002;77:32-5.
50. Zieman M, Guillebaud J, Weisberg E, Shangold GA, Fisher AC, Creasy GW. Contraceptive efficacy and cycle control with the Ortho Evra™/Evra™ transdermal system. Fertility and Sterility 2002;77:13-8.
51. Agile Therapeutics. Transdermal contraceptive delivery system (TCDS) of levonorgestrel and ethinyl estradiol (ATI-CL13). http://clinicaltrials.gov/ct2/show/NCT01236768 (accessed 27 Sep 2012). [NCT01236768].
52. Bayer Healthcare AG. US cycle control and blood pressure study. http://clinicaltrials.gov/ct2/show/NCT00920985 (accessed 27 Sep 2012). [NCT00920985].
53. Weisberg E. Comparative 12 month study of menstrually-signalled use of a combined contraceptive pill versus a combined contraceptive vaginal ring. http://www.anzctr.org.au/ACTRN12609000391279.aspx (accessed 26 Jul 2012).
54. Als-Nielsen B, Chen W, Gluud C, Kjaergard LL. Association of funding and conclusions in randomized drug trials: a reflection of treatment effect or adverse events?. Journal of the American Medical Association 2003;290:921-8.
55. Bayer Healthcare AG. Inhibition of ovulation and pharmacokinetics of transdermal ethinylestradiol (EE) and gestodene (GSD). http://clinicaltrials.gov/ct2/show/NCT00915915 (accessed 01 Oct 2012). [DOI: NCT00915915].
56. Brache V, Payan LJ, Faundes A. Current status of contraceptive vaginal rings. Contraception 2013;87(3):264-72.
57. CONSORT group. CONSORT: Transparent reporting of trials. http://www.consort-statement.org/ (accessed 15 Jul 2009).
58. Deeks JJ, Altman DG, Bradburn MJ. Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis. In: Egger M, Smith GD, Altman DG editor(s). Systematic Reviews in Health Care: Meta-analysis in Context. 2nd Edition. London: BMJ Publishing Group, 2001:285-312.
59. US Food, Drug Administration. Ortho Evra (norelgestromin/ethinyl estradiol) information. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm110402.htm (accessed 08 Nov 2012).
60. Grimes DA. Forgettable contraception. Contraception 2009;80:497-9.
61. Haag U. Technologies for automating randomized treatment assignment in clinical trials. Drug Information Journal 1998;32:7-11.
62. Heit JA, Kobbervig CE, James AH, Petterson TM, Bailey KR, Melton LJ III. Trends in the incidence of venous thromboembolism during pregnancy or postpartum: a 30-year population-based study. Annals of Internal Medicine 2005;143:697-706.
63. Henzl MR, Edwards JA. Pharmacology of progestins: 17alpha-hydroxyprogesterone derivatives and progestins of the first and second generation. In: Sitruk-Ware R, Mishell DR editor(s). Progestins and Antiprogestins in Clinical Practice. New York (NY): Marcel Dekker, 2000:101-32.
64. Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org. John Wiley & Sons, Ltd, (accessed 24 October 2012).
65. Hou MY, Hurwitz S, Kavanagh E, Fortin J, Goldberg AB. Using daily text-message reminders to improve adherence with oral contraceptives. Obstetrics and Gynecology 2010;116(3):633-40. [NCT00733707].
66. Jensen JT. Vaginal ring delivery of selective progesterone receptor modulators for contraception. Contraception. 2012/10/09 2013; Vol. 87, issue 3:314-8.
67. Langston AM, Rosario L, Westhoff CL. Structured contraceptive counseling--a randomized controlled trial. Patient Education and Counseling. 2010/09/28 2010; Vol. 81, issue 3:362-7.
68. Lete I, Doval JL, Perez-Campos E, Lertxundi R, Correa M, de la Viuda E, et al.Self-described impact of noncompliance among users of a combined hormonal contraceptive method. Contraception. 2008/03/18 2008; Vol. 77, issue 4:276-82.
69. Lexchin J, Bero LA, Djulbegovic B, Clark O. Pharmaceutical industry sponsorship and research outcome and quality: systematic review. British Medical Journal 2003;326:1167-70.
70. Moher D, Schulz KF, Altman DG. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. Lancet 2001;357:1191-4.
71. Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD). A multi-center, open-label, randomized, parallel group study to evaluate pharmacokinetic profile, effects on the mechanisms of contraceptive efficacy and safety of two progestin-only patches containing different doses of levonorgestrel (LNG) (CCN009). http://clinicaltrials.gov/ct2/show/NCT01166412 (accessed 23 Sep 2012). [DOI: NCT01166412].
72. Population Council. Licensing Opportunities. http://www.popcouncil.org/what/licensing.asp#/jQueryUITabs1-2 (accessed 12 Nov 2012).
73. Potter L, Oakley D, de Leon-Wong E, Canamar R. Measuring compliance among oral contraceptive users. Family Planning Perspectives 1996;28:154-8.
74. Raymond EG, Burke AE, Espey E. Combined hormonal contraceptives and venous thromboembolism: putting the risks into perspective. Obstetrics and Gynecology 2012; Vol. 119, issue 5:1039-44.
75. Rosenberg MJ, Waugh MS, Burnhill MS. Compliance, counseling and satisfaction with oral contraceptives: a prospective evaluation. Family Planning Perspectives 1998;30:89-92, 104.
76. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. Journal of the American Medical Association 1995;273:408-12.
77. Schulz KF, Grimes DA. Allocation concealment in randomised trials: defending against deciphering. Lancet 2002;359:614-8.
78. Sitruk-Ware R, Nath A, Mishell DR. Contraception technology: past, present and future. Contraception 2013;87(3):319-30.
79. Stanczyk FZ, Rubin A, Flood L, Foegh M. Pharmacokinetics, tolerability and cycle control of three transdermal contraceptive delivery systems containing different doses of ethinylestradiol and levonorgestrel. Hormone Molecular Biology and Clinical Investigation 2011;6(2):231-40.
80. Strauss SE, Richardson WS, Glasziou P, Haynes RB. Evidence-based Medicine: How to Practice and Teach EBM. Third Edition. New York: Churchill Livingstone, 2005.
81. Trussell J. Contraceptive failure in the United States. Contraception 2011;83(5):397-404.